LIVN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
LivaNova PLC is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company has positive catalysts such as promising clinical trial results and a solid 2026 outlook, the financial performance shows significant declines in net income and EPS, which could be a concern for long-term growth. Additionally, the stock lacks strong trading signals and has neutral sentiment from hedge funds and insiders. Holding the stock for now and monitoring its performance and developments would be a prudent approach.
The stock shows bullish moving averages (SMA_5 > SMA_20 > SMA_200), indicating a positive trend. The MACD histogram is above 0 and contracting positively, while RSI is neutral at 52.773. Key support and resistance levels are Pivot: 64.975, R1: 67.337, S1: 62.612, R2: 68.797, S2: 61.152. Overall, technical indicators suggest a mildly positive trend but no strong buy signal.
Successful OSPREY trial results for pHGNS treatment, showing significant reductions in apnea-hypopnea index and no serious adverse events.
Plans to commercialize the next-generation OSA device by 2027, targeting a large market of undiagnosed patients.
Analysts have raised price targets, citing solid 2026 outlook and consistent growth in core business areas.
Financial performance in Q4 2025 showed a significant drop in net income (-44.70% YoY) and EPS (-44.12% YoY).
Gross margin declined by 2.54% YoY, indicating potential cost pressures.
Hedge funds and insiders are neutral, showing no significant trading trends.
In Q4 2025, revenue increased by 12.15% YoY to $360.92 million, indicating solid top-line growth. However, net income dropped by 44.70% YoY to $30.91 million, and EPS fell by 44.12% YoY to $0.57. Gross margin also declined to 66.43%, down 2.54% YoY, reflecting potential cost challenges.
Analysts have raised price targets, with Barclays increasing to $73, Mizuho to $85, Baird to $83, Goldman Sachs to $73, and Stifel to $80. Most analysts maintain positive ratings, citing strong 2026 guidance, consistent growth, and promising results in core business areas.
